SCHEMBL30748767

SCHEMBL30748767

C#CCOc1cccc(Oc2ccc([N+](=O)[O-])cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
SNCA P37840 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HSPB1 P04792 1/20 0.46
FFAR1 O14842 2/20 0.46
LTA4H P09960 1/20 0.45
PTGS2 P35354 1/20 0.45
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
MAOB P27338 6/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.43
MAOA P21397 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3997879 0.84 SNCA (0.56) ALDH1A1SNCAMEN1KMT2AMAPT
SCHEMBL255260 0.83 SNCA (0.58) ALDH1A1SNCAHSPB1PTGS2MAPT
SCHEMBL27188054 0.83 ALDH1A1 (0.77) ALDH1A1KDM4EMEN1KMT2AHSPB1
SCHEMBL7632953 0.83 ALDH1A1 (0.77) ALDH1A1KDM4EMEN1KMT2AHSPB1
SCHEMBL1978185 0.81 ALDH1A1 (0.61) ALDH1A1KDM4EMEN1KMT2AHSPB1
SCHEMBL11129665 0.80 MAOB (0.56) ALDH1A1KDM4EMEN1KMT2ALTA4H
SCHEMBL24168843 0.78 ALDH1A1 (0.61) ALDH1A1KDM4EMEN1KMT2AHSPB1
SCHEMBL31691312 0.78 ALDH1A1 (0.65) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL13192707 0.78 MAOB (0.57) ALDH1A1KDM4EMEN1KMT2AFFAR1
SCHEMBL9214229 0.77 ALDH1A1 (0.73) ALDH1A1KDM4EMEN1KMT2AHSPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885SNCA 737/4885KDM4E 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.